Literature DB >> 9162069

Role of the vav proto-oncogene product (Vav) in erythropoietin-mediated cell proliferation and phosphatidylinositol 3-kinase activity.

H Shigematsu1, H Iwasaki, T Otsuka, Y Ohno, F Arima, Y Niho.   

Abstract

The vav proto-oncogene product (Vav), which is specifically expressed in hematopoietic cells, contains multiple structural motifs commonly used by intracellular signaling molecules. Although a variety of stimuli including erythropoietin (Epo) have been shown to tyrosine phosphorylate Vav, little is known about the Vav signal transduction pathway. Here, we have investigated the role of Vav in the Epo signaling pathway by characterizing its interaction with other proteins, using the human Epo-responsive cell line, F-36P. Immunoprecipitation and immunoblot analyses have demonstrated that Vav was associated with the Epo receptor (EpoR) in an Epo-independent manner and was tyrosine-phosphorylated after Epo stimulation. Furthermore, two phosphotyrosine proteins (pp70 and pp100) co-immunoprecipitated with the regulatory subunit of phosphatidylinositol 3-kinase (PI3-kinase) (p85) were identified as EpoR and Vav, respectively. The interaction between Vav and p85 was shown to be mediated through the SH2 domains of p85 by an in vitro binding assay and confirmed by the presence of in vitro PI3-kinase activity associated with Vav. Treatment of the cells with antisense-vav and -p85 abrogated Epo-induced cell proliferation and PI3-kinase activity. Finally, we found that JAK2 was associated with Vav in vivo and that Vav could be tyrosine-phosphorylated by activated JAK2 in vitro. These results suggest the possible role of JAK2 for tyrosine phosphorylation of Vav and involvement of Vav and PI3-kinase in Epo-induced proliferative signals.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9162069     DOI: 10.1074/jbc.272.22.14334

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

1.  Vav1 regulates phospholipase cgamma activation and calcium responses in mast cells.

Authors:  T S Manetz; C Gonzalez-Espinosa; R Arudchandran; S Xirasagar; V Tybulewicz; J Rivera
Journal:  Mol Cell Biol       Date:  2001-06       Impact factor: 4.272

2.  Peginesatide and erythropoietin stimulate similar erythropoietin receptor-mediated signal transduction and gene induction events.

Authors:  Jennifer M Green; Karen Leu; Angela Worth; Richard B Mortensen; David K Martinez; Peter J Schatz; Don M Wojchowski; Peter R Young
Journal:  Exp Hematol       Date:  2012-03-06       Impact factor: 3.084

3.  Vav1 Regulates T-Cell Activation through a Feedback Mechanism and Crosstalk between the T-Cell Receptor and CD28.

Authors:  Ynes A Helou; Anna P Petrashen; Arthur R Salomon
Journal:  J Proteome Res       Date:  2015-06-16       Impact factor: 4.466

4.  Signaling through CD5 activates a pathway involving phosphatidylinositol 3-kinase, Vav, and Rac1 in human mature T lymphocytes.

Authors:  S I Gringhuis; L F de Leij; P J Coffer; E Vellenga
Journal:  Mol Cell Biol       Date:  1998-03       Impact factor: 4.272

Review 5.  Targeting JAK2 in the therapy of myeloproliferative neoplasms.

Authors:  Mamatha M Reddy; Anagha Deshpande; Martin Sattler
Journal:  Expert Opin Ther Targets       Date:  2012-02-17       Impact factor: 6.902

6.  A highly selective, orally active inhibitor of Janus kinase 2, CEP-33779, ablates disease in two mouse models of rheumatoid arthritis.

Authors:  Kristine L Stump; Lily D Lu; Pawel Dobrzanski; Cynthia Serdikoff; Diane E Gingrich; Ben J Dugan; Thelma S Angeles; Mark S Albom; Mark A Ator; Bruce D Dorsey; Bruce A Ruggeri; Matthew M Seavey
Journal:  Arthritis Res Ther       Date:  2011-04-21       Impact factor: 5.156

7.  Vav1 transduces T cell receptor signals to the activation of phospholipase C-gamma1 via phosphoinositide 3-kinase-dependent and -independent pathways.

Authors:  Lucinda F Reynolds; Lesley A Smyth; Trisha Norton; Norman Freshney; Julian Downward; Dimitris Kioussis; Victor L J Tybulewicz
Journal:  J Exp Med       Date:  2002-05-06       Impact factor: 14.307

8.  Integrated analysis of recurrent properties of cancer genes to identify novel drivers.

Authors:  Matteo D'Antonio; Francesca D Ciccarelli
Journal:  Genome Biol       Date:  2013-05-29       Impact factor: 13.583

Review 9.  Erythropoietin action in stress response, tissue maintenance and metabolism.

Authors:  Yuanyuan Zhang; Li Wang; Soumyadeep Dey; Mawadda Alnaeeli; Sukanya Suresh; Heather Rogers; Ruifeng Teng; Constance Tom Noguchi
Journal:  Int J Mol Sci       Date:  2014-06-10       Impact factor: 5.923

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.